rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XBIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates

      "This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences. "Santersus is expected to bring an established clinical-stage platform, two FDA Breakthrough Device Designations and a pipeline targeting serious diseases with substantial unme

      Nov 13Yahoo FinanceXBIO
      Xenetic Biosciences: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceXBIO
      Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
      Nov 4Yahoo FinanceXBIO
      Xenetic partner doses first patient in DNase CAR T-cell study
      Oct 15Investing.comXBIO
      Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
      Oct 15Yahoo FinanceXBIO
      Xenetic Biosciences, Inc. (XBIO) Stock Price, News, Quote & History
      Oct 14Yahoo FinanceXBIO
      Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake

      The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders. Key Investor TakeawaysXenetic Biosciences (NASDAQ:XBIO) has signed a definitive share exchange agreement to acquire privately held Santersus AG in an all-stock transaction.

      Sep 16Yahoo FinanceXBIO
      Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
      Sep 16BenzingaXBIO
      Xenetic Biosciences to acquire Santersus in all-stock deal
      Sep 16Investing.comXBIO
      Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

      The combined company is expected to continue to trade on the Nasdaq Capital Market as Santersus Bio, Inc."The Proposed Transaction is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impact therapeutic target: neutrophil extracellular traps, or NETs.

      Sep 16Yahoo FinanceXBIO

      This is the newest page. Registered accounts read further back.